{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:13:50Z","timestamp":1777428830764,"version":"3.51.4"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:00:00Z","timestamp":1552608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In this article, we propose, based on a clinical case, the potential antitumor effect related to the inhibition of serotonin in neuroendocrine tumors (NETs). Currently, the only drug that exists for the symptomatic treatment of carcinoid syndrome refractory to somatostatin analogues is telotristat, based on its pivotal study, the TELESTAR trial. Based on the existing preclinical rationale, it seems that the inhibition of serotonin may have an antitumoral role in NETs. Briefly, serotonin may act as an autocrine growth factor of NETs, and it may also play an immunomodulatory role by enhancing macrophage polarization to an immunotolerant M2 phenotype. To our knowledge, this rationale for the possible antitumor effect of serotonin in NETs has not yet been published in the literature.<\/jats:p>","DOI":"10.1634\/theoncologist.2018-0776","type":"journal-article","created":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T19:08:55Z","timestamp":1552676935000},"page":"e597-e599","source":"Crossref","is-referenced-by-count":6,"title":["Inhibition of Serotonin Synthesis May Have Antitumor Activity? Long-Term Efficacy in a Patient with Gastrointestinal Neuroendocrine Tumor"],"prefix":"10.1093","volume":"24","author":[{"given":"Javier","family":"Molina-Cerrillo","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Ram\u00f3n y Cajal University Hospital, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Grande","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, MD Cancer Center, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Alonso-Gordoa","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Ram\u00f3n y Cajal University Hospital, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,3,15]]},"reference":[{"key":"2021122507241573000_R1","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1634\/theoncologist.2015-0455","article-title":"Inhibition of peripheral synthesis of serotonin as a new target in neuroendocrine tumors","volume":"21","author":"Molina-Cerrillo","year":"2016","journal-title":"The Oncologist"},{"key":"2021122507241573000_R2","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: A population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021122507241573000_R3","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2005.03.038","article-title":"Current status of gastrointestinal carcinoids","volume":"128","author":"Modlin","year":"2005","journal-title":"Gastroenterology"},{"key":"2021122507241573000_R4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MPA.0b013e3182328045","article-title":"Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population","volume":"41","author":"Beaumont","year":"2012","journal-title":"Pancreas"},{"key":"2021122507241573000_R5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome","volume":"35","author":"Kulke","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122507241573000_R6","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1002\/cncr.24533","article-title":"Autoregulatory effects of serotonin on proliferation and signaling pathways in lung and small intestine neuroendocrine tumor cell lines","volume":"115","author":"Drozdov","year":"2009","journal-title":"Cancer"},{"key":"2021122507241573000_R7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000338793","article-title":"The role of cell lines in the study of neuroendocrine tumors","volume":"96","author":"Grozinsky-Glasberg","year":"2012","journal-title":"Neuroendocrinology"},{"key":"2021122507241573000_R8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122507241573000_R9","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.4049\/jimmunol.1201133","article-title":"Serotonin skews human macrophage polarization through HTR2B and HTR7","volume":"190","author":"de las Casas-Engel","year":"2013","journal-title":"J Immunol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0776","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0776","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/7\/e597\/41918021\/oncolo_24_7_e597.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/7\/e597\/41918021\/oncolo_24_7_e597.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T07:24:37Z","timestamp":1640417077000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/7\/e597\/6439414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,15]]},"references-count":9,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,3,15]]},"published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0776","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7,1]]},"published":{"date-parts":[[2019,3,15]]}}}